Search research articles
Contact Us
Filters
Showing results (541-550 of 556) with videos related to
Page
of 56
Sort By:
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
The New England Journal of Medicine
|
March 19, 2020
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M Gross, Pamela L Wolters, Eva Dombi, et al.
The Lancet. Oncology
|
March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Metabolism
|
March 12, 2025
Glycogen drives tumour initiation and progression in lung adenocarcinoma
Harrison A Clarke, Tara R Hawkinson, Cameron J Shedlock, et al.
Science Translational Medicine
|
March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery
|
December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery
|
June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
American Journal of Human Genetics
|
July 3, 2021
Targeted long-read sequencing identifies missing disease-causing variation
Danny E Miller, Arvis Sulovari, Tianyun Wang, et al.
Page
of 56
Search research articles
Search
Showing results (541-550 of 556) with videos related to
Sort By:
Page
of 56
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
The New England Journal of Medicine
|
March 19, 2020
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M Gross, Pamela L Wolters, Eva Dombi, et al.
The Lancet. Oncology
|
March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Metabolism
|
March 12, 2025
Glycogen drives tumour initiation and progression in lung adenocarcinoma
Harrison A Clarke, Tara R Hawkinson, Cameron J Shedlock, et al.
Science Translational Medicine
|
March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery
|
December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery
|
June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
American Journal of Human Genetics
|
July 3, 2021
Targeted long-read sequencing identifies missing disease-causing variation
Danny E Miller, Arvis Sulovari, Tianyun Wang, et al.
Page
of 56